We have recently demonstrated that linkage of DNAencoding calreticulin to DNA-encoding human papillomavirus-16 E7 antigen strongly enhances the efficacy of DNA vaccines against E7-expressing tumors in animal models. In this study, as a prelude to clinical translation, we characterized the ability of DNA-encoding calreticulin linked to DNAencoding E7 antigen to generate HLA-A2-restricted E7-specific CD8 + T-cell responses in HLA-A2 (AAD) transgenic mice, as well as antitumor effects against an E7 + HLA-A2 + tumor cell line, TC-1/A2. Our results show that while vaccination with CRT/E7 DNA generates strong H-2D brestricted E7 (amino acid (aa)49-57)-specific CD8 + T-cell immune responses in both C57BL/6 and HLA-A2 (AAD) transgenic mice, no such responses were generated to HLA-A2-restricted epitopes in either type of mouse. In contrast, vaccination with DNA-encoding calreticulin linked to DNA encoding a mutant version of E7 with a deleted aa49-57 epitope leads to the generation of an HLA-A2-restricted E7 (aa11-20)-specific CTL response in HLA-A2 (AAD) transgenic mice. More importantly, vaccination with CRT/ mtE7 (del aa49-57) DNA protects against a lethal challenge with TC-1/A2 tumor cells in HLA-A2 (AAD) transgenic mice. Furthermore, our in vitro studies demonstrate that the presence of the E7 (aa49-57) epitope does not suppress presentation of the HLA-A2-restricted E7 (aa11-20) epitope through MHC class I molecules. Thus, the predominant E7 aa49-57-specific CD8+ T-cell immune response in HLA-A2 transgenic mice vaccinated with CRT/E7 is likely due to preferred expansion of E7 aa49-57-specific CD8 + T cells in vaccinated mice. These results highlight the importance of epitope immunodominance in the evaluation of immune responses in HLA-A2 (AAD) transgenic mice.
Introduction
It has been established that DNA vaccine potency can be significantly enhanced by gene gun delivery of DNA plasmids into professional antigen-presenting cells in vivo (see, for a review, Hung and Wu 1 ). We have developed several DNA vaccines against human papillomavirus-16 (HPV-16) E7 antigen using intracellular targeting strategies to enhance MHC class I and II presentation (see, for a review, Hung and Wu 1 ). We chose E7 because it is consistently expressed in most HPVassociated cancer cells, and is responsible for their malignant transformation. Thus, E7 represents an ideal target antigen for the development of vaccines and immunotherapeutic strategies against HPV-associated neoplasms. We have recently performed a head-to-head comparison of E7 DNA vaccines employing various intracellular targeting strategies, and have identified the DNA vaccine encoding calreticulin fused to full-length E7 (CRT/E7) as one of the most potent in generating E7-specific immune responses and antitumor effects. 2 Thus, CRT/E7 represents a promising therapeutic vaccine for clinical translation to control HPV-associated lesions in humans.
The identification of an HLA-A2-restricted E7-specific CTL epitope will facilitate the development of quantitative human T-cell immunological assays for characterization of E7-specific CD8 + T-cell immune responses in patients receiving effective E7 DNA vaccines. Such assays include intracellular cytokine staining, ELISPOT and MHC class I tetramer staining. HLA-A2 transgenic mice have been extensively used to identify CTL epitopes that are functional in humans and to evaluate the efficacy of candidate vaccines, since these transgenic mice may have CTL repertoires similar to those of humans. Previously, Ressing et al. 3 have identified several E7-specific HLA-A2-restricted CTL epitopes (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , YMLDLQPETT; 82-90, LLMGTLGIV; 86-93, TLGIVCPI), using HLA-A2 transgenic mice. Thus, the HLA-A2 transgenic mice may potentially be useful for evaluating HLA-A2-restricted CD8 responses with specificities correlating with those observed in humans. 4 We have acquired HLA-A2.1(AAD) transgenic mice that express a chimeric HLA class I molecule, comprising the a-1 and a-2 domains from human HLA-A*0201 and the a-3 transmembrane/cytoplasmic domain from mouse H-2D d . 5 These transgenic mice have been used by other researchers to characterize the immunogenicity and vaccine effects of several HLA-A2-restricted CTL epitopes from viral antigens. [6] [7] [8] In this study, we characterized the HLA-A2-restricted E7-specific CD8 + T-cell immune response generated by our CRT/E7 DNA vaccine in HLA-A2 (AAD) transgenic mice. We found that vaccination with CRT/E7 DNA generates strong H-2D b -restricted E7 (amino acid (aa)49-57)-specific CD8 + T-cell immune responses 9 in both C57BL/6 and HLA-A2 (AAD) transgenic mice. We also found that vaccination with CRT/mtE7 (del aa49-57) leads to the generation of an HLA-A2-restricted E7 (aa11-20)-specific CTL response in HLA-A2 (AAD) transgenic mice, suggesting that the presence of the D b -restricted E7 immunodominant epitope (aa49-57) in E7 may influence the generation of HLA-A2-restricted E7 (aa11-20)-specific CD8 + T-cell immune responses in HLA-A2 (AAD) transgenic mice that concomitantly express H-2D b molecules. Furthermore, we observed that alterations (through deletion or mutation) of the E7 gene at the regions aa49-57 and aa11-20 were able to influence the generation of HLA-A2-restricted E7-specific T-cellmediated immune responses in HLA-A2 (AAD) transgenic mice vaccinated with pcDNA3-CRT/E7. More importantly, we found that HLA-A2 (AAD) transgenic mice vaccinated with pcDNA3-CRT/mtE7 (del aa49-57) were capable of controlling a lethal challenge with HLA-A2-expressing, E7-expressing tumor cells (TC-1/A2). The clinical implications of the current study are discussed.
Results
Vaccination with CRT/E7 DNA generates strong H-2D b -restricted E7 (aa49-57)-specific CD8 + T-cell immune responses in both HLA-A2 (AAD) transgenic mice and C57BL/6 mice In order to characterize the HLA-A2-restricted E7-specific CD8 + T-cell immune response in HLA-A2 (AAD) transgenic mice vaccinated with pcDNA3-CRT/ E7, we harvested splenocytes from vaccinated mice 1 week after the last vaccination. The splenocytes were characterized for E7 peptide-specific CD8 + T-cell immune responses. As shown in Figure 1 , vaccination with pcDNA3-CRT/E7 resulted in a significant number of IFN-g-expressing E7 (aa49-57) peptide-specific CD8 + T cells in both C57BL/6 (93374.24) and HLA-A2 (AAD) transgenic mice (653770.71). In comparison, very few E7 Figure 1 Intracellular cytokine staining with flow cytometry analysis to determine E7 peptide-specific CD8 + T cells in pcDNA3-CRT/E7-vaccinated mice. C57BL/6 and HLA-A2 (AAD) transgenic mice were vaccinated with pcDNA3-CRT/E7. Splenocytes were harvested 1 week after the last vaccination. Pooled splenocytes from vaccinated mice (five per group) were stimulated in vitro with HPV-16 E7 peptides (aa11-20, aa49-57 or aa86-93) overnight. Splenocytes without stimulation with peptides were used as a negative control. Cells were stained for both CD8 and intracellular IFN-g and followed by flow cytometry analysis to identify IFN-g-secreting, E7-specific CD8 + T-cell precursors. Characterization of HLA-A2-restricted E7-specific CD8 + T-cell immune responses S Peng et al peptide-specific CD8 + T cells were generated against the previously characterized HLA-A2-restricted E7 (aa11-20) (4278.49) or E7 (aa86-93) (28.572.12) epitopes in either C57BL/6 or HLA-A2 (AAD) transgenic mice. These data indicate that vaccination of HLA-A2 (AAD) transgenic mice with pcDNA3-CRT/E7 predominantly generates H-2D b -restricted E7 (aa49-57) peptide-specific CD8 + T-cell immune responses and that only minimal amounts of HLA-A2-restricted E7 peptide-specific CD8 + T cells were generated in the vaccinated mice.
Vaccination with the DNA vaccine encoding CRT linked to E7 with a deletion of aa49-57 leads to a significant HLA-A2-restricted E7 (aa11-20) peptidespecific CD8 + T-cell immune response in HLA-A2 (AAD) transgenic mice
The failure to observe responses to the aa11-20 or aa86-93 epitopes in HLA-A2 (AAD) transgenic mice that also expressed murine H-2 molecules suggested that the potent D b -restricted E7 response might somehow be suppressing or masking weaker HLA-A2-restricted responses. To address this possibility, we created a mutant E7 gene with a deletion of aa49-57 (mtE7 (del aa49-57)) and generated a chimeric CRT/mtE7 (del aa49-57) DNA vaccine. To determine if vaccination with pcDNA3-CRT/mtE7 (del aa49-57) in HLA-A2 (AAD) transgenic mice would generate an E7-specific HLA-A2 restricted CD8 + T-cell immune response, we isolated the splenocytes 1 week after the last vaccination and pulsed the splenocytes with various E7 peptides, including (aa11-20, aa49-57, aa82-90 and aa86-93). As shown in Figure 2 , HLA-A2 (AAD) transgenic mice vaccinated with pcDNA3-CRT/mtE7 (del aa49-57) generated the highest number of HLA-A2-restricted E7 (aa11-20)-specific CD8 + T-cell precursors among all the E7 peptide-specific CD8 + T-cell precursors examined. In comparison, HLA-A2 (AAD) transgenic mice vaccinated with pcDNA3-CRT/E7 generated the highest number of H-2D b -restricted E7 (aa49-57) peptide-specific CD8 + T-cell precursors. These data suggest that the presence of the E7 49-57 aa sequence within the E7 gene of CRT/E7 DNA vaccine may influence the generation of E7 (aa11-20)-specific CD8 + T-cell immune responses in HLA-A2 (AAD) transgenic mice.
Modification of aa11-20 or aa49-57 in E7 is able to improve E7 presentation through the HLA-A2 molecule.
It has previously been demonstrated that mutation of E7 at aa57 (from Phe to Arg) decreases the binding affinity of E7 (aa49-57) to H-2D b molecules, resulting in a reduction of the tumor protection ability of E7 Characterization of HLA-A2-restricted E7-specific CD8 + T-cell immune responses S Peng et al (aa49-57). 10 It has also been shown that mutation of E7 at aa20 (from Thr to Val) was able to enhance the binding affinity of E7 (aa11-20) peptide to HLA-A2 molecules. 11 We therefore generated DNA constructs encoding CRT linked to E7 with a mutation at aa57 (CRT/mtE7 (F57R)) or a mutation at aa20 (CRT/mtE7 (T20V)). As shown in Figure 3 Vaccination of HLA-A2 (AAD) transgenic mice with pcDNA3-CRT/mtE7 (del aa49-57) protects against a lethal challenge with TC-1/A2
We performed tumor protection experiments to test whether vaccination with pcDNA3-CRT/mtE7 (del 
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+ T-cell immune responses S Peng et al aa49-57) can provide protection against tumor challenge with TC-1/A2 in HLA-A2 (AAD) transgenic mice. TC-1 cells were used as negative controls. As shown in Figure  5 , 60% of mice vaccinated with pcDNA3-CRT/mtE7 (del aa49-57) remained tumor free 6 weeks after TC-1/ A2 challenge. In contrast, all mice vaccinated with pcDNA3-CRT or without vaccination developed tumors within 2 weeks after tumor challenge. Furthermore, none of the mice challenged with TC-1 could be protected by vaccination with pcDNA3-CRT/mtE7 (del aa49-57). These data indicate that vaccination with pcDNA3-CRT/mtE7 (del aa49-57) was capable of generating strong HLA-A2-restricted antitumor effects. 
Discussion
In this study, we characterized the HLA-A2-restricted E7-specific immune response in HLA-A2 (AAD) transgenic mice. The HLA-A2 (AAD) transgenic mice used in our study express both human HLA class I heavy chains and murine H-2 class I molecules (see, for a review, Lemonnier 12 ). Our data showed that vaccination with Another approach to avoid presentation of murine H-2-restricted CTL epitope in HLA-A2 (AAD) transgenic mice is to use a new generation of HLA-A2 transgenic mice, HLA-A2.1 transgenic/H-2 class I knockout mice (also known as HHD mice). In HHD mice, the H-2 class I gene was knocked out, and a chimeric HLA-A2.1 monochain (HHD) was generated by linking the Cterminal of the human b2m covalently to the N-terminus of the chimeric HLA-A2 heavy chain (containing the a1 and a2 domains of HLA-A2.1 and the a3 domain of H-2D b ) via a peptidic arm. 12 This ensures that the HHD 
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+ T-cell immune responses S Peng et al molecule will be the only MHC class I molecule expressed on cell surfaces, ensuring that any identified CTL epitopes are HLA-A2 restricted. Thus, these HLA-A2 transgenic mice have been genetically engineered to promote usage of the human HLA class I molecules by the mouse CD8 + T cells. It will be of interest to test our DNA vaccine in these mice.
Our study agrees with previous studies, which showed that modification of the anchor residues of the E7 aa11-20 epitope 11 or the E7 aa49-57 epitope 10 can affect CTL responses elicited by vaccination with E7-encoding DNA vaccines. Our data suggest that a modified aa49-57 epitope can reduce presentation of the immunodominant aa49-57 epitope in mice vaccinated with CRT/E7 DNA, resulting in increased E7 (aa11-20)-specific CD8 + T-cell immune responses in vaccinated mice (see Figure 3) . Furthermore, our data also suggest that the aa11-20 epitope can be modified to enhance its presentation on antigen-expressing dendritic cells (see Figure 7) as well as to enhance E7 (aa11-20)-specific CD8 + T-cell immune responses in vaccinated mice (see Figure 3) . The understanding that modification of peptide anchor residues can influence immunodominance makes possible the design of more effective multiepitope vaccines.
We have developed an HLA-A2-expressing tumor model, TC-1/A2, that can naturally process and present E7 antigen via HLA-A2 molecules. This model should be useful for assays of HLA-A2-restricted E7-specific antitumor responses and antitumor effects. Eiben et al 15 have created a transgenic cell line, HLF16, that is tumorigenic in HLA-A*0201 mice by transfecting heart lung fibroblasts from HLA-A*0201 mice with HPV-16 E6 and E7 oncogenes and H-Ras V12. In that tumor cell line, the H-2D b -restricted HPV-16 E7 immunodominant epitope (aa49-57) was removed from the E7 construct to ensure that all antitumor responses were mediated through the HLA-A*0201-restricted epitopes. While the HLF16 tumor cell line is potentially useful, the HLA-A2 expression level is not high and it requires injection with a large dose (2 Â 10 6 cells/mouse) to develop stable tumor growth in challenged mice. 15 In comparison, our TC-1/ A2 model has the advantage of high HLA-A2 expression and smaller tumor challenge dose for tumor growth than the HLF16 tumor cell line (1 Â 10 4 cells versus 2 Â 10 6 cells). Thus, we have selected the TC-1/A2 tumor cell line for our study. The TC-1/A2 tumor model could also be transfected with other tumor-associated antigens and used for testing the antitumor effect generated by other antigen-specific vaccines (e.g. MART-1 for a melanoma model or Her2/neu for an ovarian model).
Our data indicate that vaccination with CRT/mtE7 (del aa49-57) DNA vaccine generated a significant HLA-A2-restricted E7 (aa11-20)-specific CD8 + T-cell immune response, but did not generate E7 (aa82-90)-or E7 (aa86-93)-specific CD8 + T-cell immune responses in vaccinated mice (see Figure 2) . Our findings agree with previous studies. 16, 17 Bauer et al. 16 reported that HLA-A2 transgenic mice vaccinated with the E7 protein did not produce a detectable E7 (aa86-93)-specific CTL response. Similarly, Street et al. 17 also found that the E7 epitopes (aa82-90 and aa86-93) were not processed out of either endogenously expressed or immunization-introduced E7 in HLA-A2 transgenic mice. In comparison, Eiben et al. In this study, we observed that HLA-A2 (AAD)-expressing dendritic cell lines transfected with CRT/E7 DNA were capable of activating E7 (aa11-20)-specific CD8 + T cells in a similar level compared to dendritic cells Characterization of HLA-A2-restricted E7-specific CD8 + T-cell immune responses S Peng et al transfected with CRT/mtE7 (del aa49-57) (see Figure 7) . Thus, our data suggest that the presence of the E7 (aa49-57) epitope within the E7 gene does not suppress the presentation of E7 (aa11-20) epitope through HLA-A2 molecules. However, we observed that the HLA-A2 (AAD) transgenic mice vaccinated with CRT/E7 generated strong E7 (aa49-57)-specific and weak E7 (aa11-20)-specific CD8
+ T-cell immune responses in vaccinated HLA-A2 transgenic mice (see Figures 1 and 2) . Taken together, our results suggest that there is a preferred expansion of E7 (aa49-57)-specific CD8 + T cells in CRT/E7 DNA-vaccinated mice.
In summary, we have demonstrated that vaccination with CRT/E7 DNA can generate a strong HLA-A2-restricted E7 (aa11-20) CD8 + T-cell immune response when the H-2D b -restricted E7 (aa49-57) immunodominant epitope is deleted or suppressed in the E7 gene of the CRT/E7 DNA vaccine. Furthermore, we have shown that HLA-A2 (AAD) transgenic mice vaccinated with the CRT/E7 DNA vaccine are capable of preventing tumor growth after challenge with TC-1/A2 cells. These results are encouraging for our planned clinical trials using the pNGVL4a-CRT/E7 (detox) DNA vaccine 2 since they suggest that our CRT/E7 vaccine strategy may be capable of eliciting HLA-A2-restricted E7-specific CD8 + T-cell immune responses and possible therapeutic against HPV-associated lesions in vaccinated individuals. It will be interesting to compare the results of these preclinical studies with the results of our future clinical trials.
Materials and methods

Plasmid DNA constructs and preparation
The generation of pcDNA3-CRT, pcDNA3-E7 and pcDNA3-CRT/E7 has been described previously. 18 To generate pcDNA3-CRT/mtE7 (del aa49-57), we first generated the mtE7 (del aa49-57) gene by polymerase chain reaction (PCR). The DNA fragment encoding aa1-48 of E7 was generated by PCR using a pair of primers (5 0 tttgaattcatgcatggagatacacctaca3 0 and 5 0 ctggacaagcagaa ccggactgttgcaagtgtgactctac3 0 ) and pcDNA3-E7 as a template. The DNA fragment encoding aa58-98 of E7 was generated by PCR using a pair of primers (5 0 gtaga gtcacacttgcaacagtccggttctgcttgtccag3 0 and 5 0 gggaagcttttat ggtttctgagaacagat3 0 ) and pcDNA3-E7 as a template. The mtE7 (del aa49-57) DNA fragment was generated by PCR using primers (5 0 tttgaattcatgcatggagatacacctaca3 0 and 5 0 gggaagcttttatggtttctgagaacagat3 0 ) and E7 DNA fragments encoding aa1-48 and aa58-98 as templates. This final amplified product was further cloned into the EcoRI/HindIII sites of pcDNA3-CRT to generate pcDNA3-CRT/mtE7 (del aa49-57).
To create pcDNA3-CRT/mtE7 (T20V), we used PCR to generate the mtE7 (T20V) DNA fragment. The E7 DNA fragment of nucleotides 1-80 containing a mutation at the position 20 aa of E7 (from Thr to Val) was amplified using a pair of primers (5 0 tttgaattcatgcatggagatacacct aca3 0 and 5 0 tgctcataacagtagagatctactgtctctggttgcaaatcta3 0 ) and pcDNA3-E7 as a template. The E7 DNA fragment of nucleotides 38-297 containing the same mutation was amplified using a pair of primers (5 0 tagatttgcaaccagag acagtagatctctactgttatgagca3 0 and 5 0 gggaagcttttatggtttct gagaacagat3 0 ) and pcDNA3-E7 as a template. The final mtE7 (T20V) DNA fragment was generated by PCR using a pair of primers (5 0 tttgaattcatgcatggagatacac ctaca3 0 and 5 0 gggaagcttttatggtttctgagaacagat3 0 ) and the E7 DNA fragments of nucleotides 1-80 and nucleotides 38-297 as templates. The amplified product was further cloned into the EcoRI/HindIII sites of pcDNA3-CRT to generate pcDNA3-CRT/mtE7 (T20V).
To produce pcDNA3-CRT/mtE7 (F57R), we used PCR to generate the mtE7 (F57R) DNA fragment. The E7 DNA fragment of nucleotides 1-191 containing a mutation at the position 57 aa of E7 (from Phe to Arg) was amplified using a pair of primers (5 0 tttgaattcatgcatggagatacaccta ca3 0 and 5 0 gtagagtcacacttgcaacaccgggttacaatattgtaatg gg3 0 ) and pcDNA3-E7 as a template. The E7 DNA fragment of 149-297 nucleotide containing the same mutation was amplified by using a pair of primers (5 0 cccattacaatattgtaacccggtgttgcaagtgtgactctac3 0 and 5 0 gg gaagcttttatggtttctgagaacagat3 0 ) and pcDNA3-E7 as a template. The final E7 (F57R) DNA fragment was generated by PCR using a pair of primers (5 0 tttgaa ttcatgcatggagatacacctaca3 0 and 5 0 gggaagcttttatggtttctg agaacagat3 0 ) and the E7 DNA fragments of nucleotides 1-191 and nucleotides 149-297 as templates. The amplified product was further cloned into the EcoRI and HindIII sites of pcDNA3-CRT to generate pcDNA3-CRT/mtE7 (F57R).
To generate pMSCV-HLA-A2 (AAD), the DNA fragment encoding the full-length HLA-A2 (AAD) chimeric protein was amplified with a pair of primers (5 0 tttagatctatggccgtcatggcgccccga3 0 and 5 0 tttgaattctcac actttacaatctgggag3 0 ) and total RNA from the splenocytes of HLA-A2 (AAD) transgenic mice as templates using Superscript One-Step RT-PCR kit (Invitrogen, Carlsbad, CA, USA). The amplified DNA fragment was further cloned into BglII/EcoRI sites of pMSCVpuro retroviral vector (Clontech, Palo Alto, CA, USA). To generate pcDNA3-HLA-A2 (AAD), the amplified HLA-A2 (AAD) DNA fragment was cloned into BglII/EcoRI sites of pcDNA3-plus vector (Invitrogen, Carlsbad, CA, USA). The accuracy of these constructs was confirmed by DNA sequencing. DNA was amplified in Escherichia coli DH5a and purified as described previously. 19 
Peptides
Peptides representing defined HPV-16 E7 CTL epitopes, including H-2D b -restricted aa49-57 (RAHYNIVTF), 9 and HLA-A*0201-restricted aa11-20 (YMLDLQPETT), aa86-93 (TLGIVCPI) and aa82-90 (LLMGTLGIV), 3 were synthesized by Macromolecular Resources (Denver, CO, USA) at a purity of greater than or equal to 70% (verified by HPLC).
Cells
DC-1 cells were generated from the dendritic cell line 20 provided by Dr Kenneth Rock at the University of Massachusetts. With continued passage, we have generated subclones of DCs (DC-1) that can be easily transfected.
21 T2 (174 Â CEM.T2) cells deficient in the transporters for antigen processing (TAP) were obtained from American Type Culture Collection (ATCC CRL-1992, Manassas, VA, USA). TC-1 cells were generated as described previously. 22 To generate TC-1/A2, the construct pMSCV-HLA-A2 (AAD) was transfected into Phoenix packaging cell line and the retrovirus virioncontaining supernatant was collected 48 h after transfecCharacterization of HLA-A2-restricted E7-specific CD8 + T-cell immune responses S Peng et al tion. The supernatant was filtered with 0.45-mm cellulose acetate sterile filter and used to infect TC-1 in the presence of 8 mg/ml polybrene (Sigma, St Louis, MO, USA). At 1 day after retroviral transduction, the viral supernatant was replaced with normal culture medium, and when the cells reach 70% confluency, puromycin (7.5 mg/ml) was used to select for cells with integrated HLA-A2 (AAD). The expression level of HLA-A2 (AAD) chimeric protein was verified by staining the cells with anti-HLA-A2 antibody, BB7.1 (Pharmingen, San Diego, CA, USA) and analyzing by flow cytometry. All cells were maintained in RPMI medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, and 20 mM HEPES, 50 mM b-mercaptoethanol, 100 IU/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (Gemini Bio-Products, Woodland, CA, USA).
Mice
HLA-A*0201/D d (AAD) transgenic female C57BL/6 mice, 6-8 weeks of age, were kindly provided by Dr Victor Engelhard at the University of Virginia Health Sciences Center. 5 These transgenic mice express a chimeric HLA class I molecule comprising the a-1 and a-2 domains of HLA-A*0201, and the a-3 transmembrane and cytoplasmic domain of H-2D
d . This allows the murine CD8 molecule on the murine CD8 + T cells to interact with the syngeneic a-3 domain of the chimeric MHC class I molecule. Wild-type C57BL/6 female mice (6-8 weeks old) were also purchased from the National Cancer Institute. All animals were maintained under specific pathogen-free conditions, and all procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
DNA vaccination
DNA-coated gold particles were prepared and DNA vaccination was performed using a helium-driven gene gun (BioRad Laboratories Inc., Hercules, CA, USA) according to a protocol described previously. 19 pcDNA3-CRT, pcDNA3-CRT/E7, pcDNA3-CRT/mtE7 (del aa49-57), pcDNA3-CRT/mtE7 (F57R) or pcDNA3-CRT/mtE7 (T20V) DNA-coated gold particles were delivered to the shaved abdominal region of mice using a helium-driven gene gun (BioRad Laboratories, Hercules, CA, USA) with a discharge pressure of 400 psi. Mice were immunized with 2 mg of the various DNA vaccines via gene gun and were boosted with the same dose and regimen 1 week later.
Intracellular cytokine staining and flow cytometry analysis
Splenocytes from vaccinated mice (five per group) were harvested 1 week after the last vaccination. Pooled splenocytes from naïve or vaccinated groups of C57BL/ 6 mice or HLA-A2 (AAD) transgenic mice were incubated overnight with 1 mg/ml of E7 peptide, (H- Cells were then washed once with FACScan buffer and stained with phycoerythrin-conjugated monoclonal rat anti-mouse CD8 antibody (clone 53.6.7; BD Pharmingen). Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, USA). Intracellular IFN-g was stained with FITCconjugated rat anti-mouse IFN-g. All antibodies were purchased from BD Pharmingen. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA, USA).
In vitro generation of HLA-A*0201 restricted HPV-16 E7 (11-20)-specific CTL lines
Splenocytes from pcDNA3-CRT/mtE7 (del aa49-57)-immunized HLA-A2 (AAD) transgenic mice were harvested 1 week after the last vaccination. These splenocytes were stimulated with irradiated TC-1/A2 tumor cells in the presence of murine IL-2 (20 IU/ml). The cells were restimulated every week for at least 2 months. The specificity of the CTL lines was tested by intracellular IFN-g staining or chromium release CTL assay using HLA-A2-restricted HPV-16 E7 (aa11-20) peptide-pulsed T2 cells as target cells.
CTL assay
Lytic activity of T cells was assessed using a standard chromium release assay. All target cells including TC-1 and TC-1/A2 cells were labeled with 100 mCi 51 Cr/10 6 cells at 371C for 90 min. T2 target cells pulsed with HPV-16 E7 peptide (aa11-20) for 2 h at 371C at the concentration of 1 mg/ml before chromium labeling were used as positive control cells. After extensive washing, the labeled target cells were incubated with HLA-A2-restricted E7 (aa11-20) peptide-specific CD8 + T-cell lines at various effector to target cell ratios in triplicate 96-well U-bottomed plates. Negative controls included wells containing target cells but no effector cells (i.e. background). A measure of 100 ml of supernatants was harvested after a 4-h incubation, and 51 Cr release was quantitated using a gamma counter. Results are expressed as percent cytotoxicity7s.d. calculated from the following formula: percent specific lysisÀ[experimental release valueÀspontaneous release value)/(maximum release valueÀspontaneous release value)] Â 100, where spontaneous release value represents counts in supernatants from wells containing target cells in medium only, and maximum release value represents counts in supernatant from wells containing target cells in medium supplemented with 10% SDS.
In vivo tumor protection experiment
For the tumor protection experiment, HLA-A2 (AAD) transgenic C57BL/6 mice (five per group) were immunized via gene gun with 2 mg of pcDNA3 without insert, pcDNA3-CRT/E7 or pcDNA3-CRT/mtE7 (del aa49-57) DNA. Mice were boosted with the same dose three times at 1-week intervals. At 1 week after the last vaccination, mice were subcutaneously challenged with 1 Â 10 5 TC-1/ A2 or TC-1 tumor cells in the right leg, and then monitored by inspection and palpation twice a week. The day of the first gene gun vaccination was considered the starting day for counting postoperative survival days. Analysis was performed using SAS version 6.12 (SAS Characterization of HLA-A2-restricted E7-specific CD8 + T-cell immune responses S Peng et al Institute Inc., Cary, NC, USA). Their percentage of tumor-free mice was analyzed according to KaplanMeier methods. Statistical significance was tested using log-rank statistics.
In vitro T2 peptide-binding assay
The in vitro T2 peptide-binding assay was performed as described previously with a minor modification. 23 Briefly, 1 Â 10 5 T2 cells were pulsed with HPV-16 E7 (aa49-57) peptide (30 mg/ml) or HPV-16 E7 (aa11-20) peptide (30 mg/ml) in serum-free RPMI-1640 medium in a 96-well culture plate for 24 h at 371C. In another set of experiments, T2 cells were pulsed with 30 mg/ml of HPV-16 E7 (aa49-57) peptide 3 h before they were pulsed with HPV-16 E7 (aa11-20) peptide (30 mg/ml) for 24 h at 371C. The peptide-pulsed T2 cells were then washed once with FACS wash buffer and stained with antihuman HLA-A2 monoclonal antibody antibody (clone BB7.2, Cat. No. 551285, BD Pharmingen, San Diego, CA, USA), followed by flow cytometry analysis. + T cells was characterized using intracellular cytokine staining for IFN-g secretion using methods as described above.
